Skip to main content

Tweets

#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo ➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02) ➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01) #ACR24 @RheumNow

Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )

1 year 5 months ago
🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119

Bella Mehta @bella_mehta ( View Tweet )

1 year 5 months ago
Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
Are you pts using cannabis? In Canada - 20% reported using w/in past 2 years Use for pain, sleep, anxiety 78% noted efficacy Compare to another study said 57% stopped due to inefficacy, 28% AEs - very diff result 70% did not tell their doc 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/6NAECW5MJK
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
Medical cannabis in the USA today Variation in state practice on recreational/medical/decriminalization 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/9Ex3lge6KO
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe
Adela Castro @AdelaCastro222 ( View Tweet )
1 year 5 months ago
In the SPACE cohort, patients with chronic back pain suspected of axial spondyloarthritis often receive a diagnosis within 35 months from symptom onset. Key determinants for early diagnosis include HLA-B27 positivity and sacroiliitis on imaging. Early diagnosis can be a game… https://t.co/RrcrtRoMfL

Antoni Chan MD (Prof) @synovialjoints ( View Tweet )

1 year 5 months ago
#0584🔬Real-World PsA Study:Tofacitinib ➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo ➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%). ➡️No significant differences mono v combo outcomes 🩺Tofa effective in diverse PsA population #ACR24 @RheumNow

Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )

1 year 5 months ago
With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 5 months ago
Cannabis and Physical Function Very small effects on meta-analysis PO cannabis - 4% benefit (0.1-8%) of achieving at least MID of SF36 function scale 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/qQOYt1m3ub
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Can multidisciplinary clinics improve quality of care for PsA? Abstract 0596: Multidisciplinary care in PsA associated with ↓ time to first biologic, ↑ dermatology & nurse visits, and better CV risk assessment. #ACR24 @RheumNow https://t.co/2OnUR6te63
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 5 months ago
×